PHARMACY

Kroger, GoodRx launch Kroger Rx Savings Club

BY David Salazar

Kroger has introduced a new way for its patients to save money. The company on Wednesday launched its Rx Savings Club, which it developed in partnership with prescription drug savings company GoodRx.

The Kroger Rx Savings Club — announced on the heels of its acquiring files from 42 Shopko pharmacies — offers patients discounts on common generic medications for such conditions as diabetes, asthma, mental health issues, women’s health, gastrointestinal health and heart health. Then program offers three tiers of low-cost medications — free 30-day and 90-day prescriptions; $3 30-day and $6 90-day prescriptions; and $6 30-day and $12 90-day prescriptions.

“Kroger is redefining the customer experience by introducing new Wellness Your Way offerings like the Kroger Rx Savings Club,” said Colleen Lindholz, president of Kroger Health. “Kroger operates nearly 2,200 pharmacies, serving millions of customers across America. Our new partnership with GoodRx provides cost savings for our customers in a simple, practical way and enables us to live our Kroger Health vision of helping people lead healthier lives.”

Kroger noted that more than 200 million prescriptions are left at the pharmacy because patients can’t afford them. Free medications include high blood pressure treatment amlodipine (brand name Norvasc), metformin IR for diabetes (brand name Glucophage); sertraline (brand name Zoloft) for mental health; and montelukast (brand name Singulair) for asthma, among others. The most popular prescription in America, according to GoodRx, atorvastatin, is in the tier that offers 30-day fills for $6 and 90-day fills for $12.

To join the Rx Savings Club, patients pay an annual fee of $36 for individuals or $72 for families of up to six people.

“Our mission is to help lower the cost of prescriptions in America, and we are very pleased to have worked with Kroger to develop such a significant Rx savings program,” said Jim Sheninger, GoodRx’s Pharmacy Strategy Officer. “The popularity of the medications included in these discounts, coupled with the extra low-cost pricing tiers, should result in meaningful savings for patients and families—savings that are absolutely critical in this high-priced healthcare landscape.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Shopko sells Rx files from 42 stores to Kroger

BY David Salazar

A new deal between Shopko and Kroger will see Kroger buying the files from 42 of Green Bay, Wis.-based Shopko’s stores. The stores — which only make up a portion of the retailer’s 227 pharmacy locations, but 25 of its 72 Wisconsin pharmacies — will see the pharmacies closed, with main stores and optical centers remaining open.

The companies said Kroger banners would service Shopko patients’ prescription needs. The locations include pharmacy counters in Idaho, Montana, Utah, Washington and Wisconsin.

Shopko and Kroger did not disclose financial terms of the deal. Kroger CEO Randy McMullen told the Milwaukee Journal-Sentinel that the purchase is part of the company’s efforts to increase its presence in Wisconsin. He noted that Shopko pharmacy associates would be interviewed to “hopefully continue their careers with us.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Gilead Sciences names Daniel O’Day chairman and CEO

BY Sandra Levy

Gilead Sciences’ board of directors has named Daniel O’Day chairman of the board and CEO, effective March 1, 2019.

O’Day is currently the CEO of Roche Pharmaceuticals and has held the position since 2011. Prior to this, he led Roche Diagnostics. His career spans three decades of diverse leadership roles across North America, Asia Pacific and Europe.

Gregg Alton will serve as interim CEO from Jan. 1, 2019 until March 1, 2019. Alton has held a number of executive positions at Gilead over the past 20 years, with experience in legal, medical affairs, policy and commercial. He previously served as general counsel, and in August of this year was appointed chief patient officer.

“Following a comprehensive search, the board became convinced that Dan is the right leader to bring Gilead into the future,” Gilead Sciences’ board of directors chairman John Martin said. “He is uniquely qualified to take on this role given his track record of success in highly scientific and competitive therapeutic areas, deep understanding of the evolving healthcare environment around the world, and unwavering commitment to driving innovation across all aspects of a business, which will serve Gilead and our stakeholders well. Additionally, Dan brings expertise and values that are aligned with our organization, and I, along with Gilead’s entire board, am confident in his ability to work alongside our talented leadership team and deliver on our ambitious goals.”

Martin will step down from the company’s board of directors, effective March 1, 2019. John Milligan will step down from his role as president and CEO, and as a member of the board at the end of 2018.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?